U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H11N.C6H8O7
Molecular Weight 313.3032
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PHENETHYLAMINE CITRATE

SMILES

NCCC1=CC=CC=C1.OC(=O)CC(O)(CC(O)=O)C(O)=O

InChI

InChIKey=CTBJILANYAWODF-UHFFFAOYSA-N
InChI=1S/C8H11N.C6H8O7/c9-7-6-8-4-2-1-3-5-8;7-3(8)1-6(13,5(11)12)2-4(9)10/h1-5H,6-7,9H2;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

HIDE SMILES / InChI

Molecular Formula C8H11N
Molecular Weight 121.1796
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C6H8O7
Molecular Weight 192.1235
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

β-phenylethylamine (2-phenylethylamine) is a small amine containing alkaloid synonymous with phenethylamine and the acronym PEA; in the human body it has a neuromodulator/neurotransmitter role and is known as a trace amine due to its low quantity relative to other bioactive amino acids. PEA was characterized as a substrate for type B monoamine oxidase. PEA functions by activating trace amine receptors (including TAAR1 and TAAR2) thereby regulating monoamine turnover. Ring-substituted phenethylamines, commonly known as 2Cs, are designer drugs that are emerging as new drugs of abuse. PEA administration may be therapeutic in selected depressed patients.

Originator

Sources: Nencki M. Festchrift für 40 jähriges Jubiläum des Prof Valentin. Bern: 1876.
Curator's Comment: reference retrieved from https://www.ncbi.nlm.nih.gov/pubmed/17888514

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.3 µM [EC50]
Target ID: Q9P1P5
Gene ID: 9287.0
Gene Symbol: TAAR2
Target Organism: Homo sapiens (Human)
0.43 nM [EC50]
Conditions
PubMed

PubMed

TitleDatePubMed
Role of copper ion in bacterial copper amine oxidase: spectroscopic and crystallographic studies of metal-substituted enzymes.
2003-01-29
Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves.
2003-01
Degradation of benzyldimethylalkylammonium chloride by Aeromonas hydrophila sp. K.
2003
Analysis of enantiomers of chiral phenethylamine drugs by capillary gas chromatography/mass spectrometry/flame-ionization detection and pre-column chiral derivatization.
2002-12-31
[Localization of non-monoaminergic aromatic L-amino acid decarboxylase neurons (D-neurons) in the human striatum and their functional significance].
2002-12
Synthesis of 3-alkyl(aryl)-4-alkylidenamino-4,5-dihydro-1H-1,2,4-triazol-5-ones and 3-alkyl-4-alkylamino-4,5-dihydro-1H-1,2,4-triazol-5-ones as antitumor agents.
2002-12
The effects of acute and subchronic treatment with fluoxetine and citalopram on stimulus control by DOM.
2002-12
Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.
2002-11-21
[Tetrahydroisoquinoline derivatives as possible Parkinson's disease-inducing substances].
2002-11
Plausible molecular mechanism for activation by fumarate and electron transfer of the dopamine beta-mono-oxygenase reaction.
2002-10-01
Production of amines in equine cecal contents in an in vitro model of carbohydrate overload.
2002-10
Major depressive episodes and diet pills.
2002-10
Stimulation of the catecholaminergic and serotoninergic neurons in the rat brain by R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane, (-)-BPAP.
2002-09-20
1-(Benzofuran-2-yl)-2-(3,3,3-trifluoropropyl)aminopentane HCl, 3-F-BPAP, antagonizes the enhancer effect of (-)-BPAP in the shuttle box and leaves the effect of (-)-deprenyl unchanged.
2002-09-13
Formation of biogenic amines in a typical semihard Italian cheese.
2002-09
Increased urine phenylethylamine after methylphenidate treatment in children with ADHD.
2002-09
High-performance liquid chromatographic determination of biogenic amines in poultry carcasses.
2002-08-28
Content of biogenic amines in a Chardonnay wine obtained through spontaneous and inoculated fermentations.
2002-08-14
Rapid simultaneous determination of amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine, 3,4-methylenedioxymethamphetamine, and 3,4-methylenedioxyethylamphetamine in urine by solid-phase extraction and GC-MS: a method optimized for high-volume laboratories.
2002-08-09
A sensitive method for determining levels of [-]-2,5,-dimethoxy-4-methylamphetamine in the brain tissue.
2002-08-08
Probing the catalytic mechanism of Escherichia coli amine oxidase using mutational variants and a reversible inhibitor as a substrate analogue.
2002-08-01
[Human striatal D-neurons and their significance].
2002-08
Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.
2002-08
Characterization of selected Spanish table wine samples according to their biogenic amine content from liquid chromatographic determination.
2002-07-31
Monoamine-dependent production of reactive oxygen species catalyzed by pseudoperoxidase activity of human hemoglobin.
2002-06
Application of ligand SAR, receptor modeling and receptor mutagenesis to the discovery and development of a new class of 5-HT(2A) ligands.
2002-06
Monoamine oxidase A and B activities in embryonic chick hepatocytes: differential regulation by retinoic acid.
2002-06
Simultaneous separation of common mono- and divalent cations on a calcinated silica gel column by ion chromatography with indirect photometric detection and aromatic monoamines-oxalic acid, containing crown ethers, used as eluent.
2002-05-17
Analysis of conserved active site residues in monoamine oxidase A and B and their three-dimensional molecular modeling.
2002-05-10
Phenylethylamine induces an increase in cytosolic Ca2+ in yeast.
2002-05
[Decreased beta-phenylethylamine in urine of children with attention deficit hyperactivity disorder and autistic disorder].
2002-05
[Neuroimaging and neurochemical studies of Rett syndrome].
2002-05
Heart rate dynamics in monoamine oxidase-A- and -B-deficient mice.
2002-05
Intercalated organic-inorganic perovskites stabilized by fluoroaryl-aryl interactions.
2002-04-22
Geometry-affinity relationships of the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene.
2002-04-11
An MCASE approach to the search of a cure for Parkinson's Disease.
2002-04-02
Cp*(2)TiMe(2): an improved catalyst for the intermolecular addition of n-alkyl- and benzylamines to alkynes.
2002-03-22
Inhibition of copper amine oxidases by pyridine-derived aldoximes and ketoximes.
2002-03-07
Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease.
2002-03
Spectroscopic evidence in support of horseradish peroxidase compound II-catalyzed oxidation of salicylic acid but not of phenylethylamine.
2002-03
Increased baroreceptor response in mice deficient in monoamine oxidase A and B.
2002-03
Stereospecific cleavage of carbon-phosphorus bonds: stereochemical course of the phosphinoyl curtius (Harger) reaction.
2002-02-09
High-level expression of human liver monoamine oxidase A in Pichia pastoris: comparison with the enzyme expressed in Saccharomyces cerevisiae.
2002-02
A TLC visualisation reagent for dimethylamphetamine and other abused tertiary amines.
2002-01-17
Enzymatic decarboxylation of tyrosine and phenylalanine to enhance volatility for high-precision isotopic analysis.
2002-01-15
Do we know the mechanism of chiral recognition between cyclodextrins and analytes?
2002-01-15
Automated headspace solid-phase microextraction and in-matrix derivatization for the determination of amphetamine-related drugs in human urine by gas chromatography-mass spectrometry.
2002-01
The enigma of conditioned taste aversion learning: stimulus properties of 2-phenylethylamine derivatives.
2002
Psychomotor stimulant effects of beta-phenylethylamine in monkeys treated with MAO-B inhibitors.
2001-12
Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug.
2001
Patents

Sample Use Guides

Early research shows that taking 10-60 mg of phenethylamine by mouth per day along with 5 mg of the antidepressant selegiline (Anipryl, Eldepryl) twice per day for 4 weeks relieves depression in 60% of people. Of the people who respond to initial treatment with phenethylamine plus selegiline, 86% show continued depression relief when treated for up to 50 weeks. Excretion study of phenethylamine in man: single oral dose of 300 mg. Rats: 20, 40, 100 mg/kg ip or 1.0, 2.5, and 5.0 mg/kg iv
Route of Administration: Other
1 uM phenethylamine alters monoamine transporter function in vitro
Substance Class Chemical
Created
by admin
on Wed Apr 02 12:03:40 GMT 2025
Edited
by admin
on Wed Apr 02 12:03:40 GMT 2025
Record UNII
235L88TMD3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PHENETHYLAMINE CITRATE
Common Name English
BENZENEETHANAMINE, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1)
Preferred Name English
Code System Code Type Description
SMS_ID
100000090347
Created by admin on Wed Apr 02 12:03:40 GMT 2025 , Edited by admin on Wed Apr 02 12:03:40 GMT 2025
PRIMARY
FDA UNII
235L88TMD3
Created by admin on Wed Apr 02 12:03:40 GMT 2025 , Edited by admin on Wed Apr 02 12:03:40 GMT 2025
PRIMARY
CAS
84473-65-4
Created by admin on Wed Apr 02 12:03:40 GMT 2025 , Edited by admin on Wed Apr 02 12:03:40 GMT 2025
PRIMARY
PUBCHEM
57354249
Created by admin on Wed Apr 02 12:03:40 GMT 2025 , Edited by admin on Wed Apr 02 12:03:40 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY